CN107073081A - Elsiglutide治疗胃肠道黏膜炎包括化疗诱发的腹泻的应用 - Google Patents

Elsiglutide治疗胃肠道黏膜炎包括化疗诱发的腹泻的应用 Download PDF

Info

Publication number
CN107073081A
CN107073081A CN201580060760.4A CN201580060760A CN107073081A CN 107073081 A CN107073081 A CN 107073081A CN 201580060760 A CN201580060760 A CN 201580060760A CN 107073081 A CN107073081 A CN 107073081A
Authority
CN
China
Prior art keywords
elsiglutide
chemotherapy
days
cycles
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580060760.4A
Other languages
English (en)
Chinese (zh)
Inventor
鲁本·焦尔吉诺
西蒙娜·隆科罗尼
塞尔玛·卡卡尼勒
F·特兰托
里卡尔多·斯培西亚
塞西莉亚·莫雷希诺
C·B·克努森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sealand Pharmaceutical Co Ltd
Helsinn Healthcare SA
Original Assignee
Sealand Pharmaceutical Co Ltd
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sealand Pharmaceutical Co Ltd, Helsinn Healthcare SA filed Critical Sealand Pharmaceutical Co Ltd
Publication of CN107073081A publication Critical patent/CN107073081A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580060760.4A 2014-09-10 2015-09-02 Elsiglutide治疗胃肠道黏膜炎包括化疗诱发的腹泻的应用 Pending CN107073081A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048520P 2014-09-10 2014-09-10
US62/048,520 2014-09-10
PCT/IB2015/001922 WO2016038455A1 (en) 2014-09-10 2015-09-02 Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea

Publications (1)

Publication Number Publication Date
CN107073081A true CN107073081A (zh) 2017-08-18

Family

ID=54548212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580060760.4A Pending CN107073081A (zh) 2014-09-10 2015-09-02 Elsiglutide治疗胃肠道黏膜炎包括化疗诱发的腹泻的应用

Country Status (18)

Country Link
US (1) US20160067311A1 (enExample)
EP (1) EP3191115A1 (enExample)
JP (1) JP2017532308A (enExample)
KR (1) KR20170052661A (enExample)
CN (1) CN107073081A (enExample)
AR (1) AR103119A1 (enExample)
AU (1) AU2015313919A1 (enExample)
BR (1) BR112017004577A2 (enExample)
CA (1) CA2959110A1 (enExample)
CL (1) CL2017000563A1 (enExample)
EA (1) EA201790552A1 (enExample)
IL (1) IL250928A0 (enExample)
MA (1) MA40623A (enExample)
MX (1) MX2017003166A (enExample)
PH (1) PH12017500426A1 (enExample)
SG (1) SG11201701690WA (enExample)
TW (1) TW201613634A (enExample)
WO (1) WO2016038455A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115054683A (zh) * 2022-05-19 2022-09-16 唐颢 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
TWI791539B (zh) * 2017-06-16 2023-02-11 丹麥商西蘭製藥公司 用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
JOP20220339A1 (ar) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163483A (zh) * 2005-04-22 2008-04-16 诺瓦西股份有限公司 使用活性维生素d化合物或其模拟物治疗、预防和缓解与化疗和放疗有关的肺部疾患
CN101171262A (zh) * 2005-05-04 2008-04-30 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
CN102711802A (zh) * 2009-10-23 2012-10-03 辉凌公司 肽glp-2激动剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163483A (zh) * 2005-04-22 2008-04-16 诺瓦西股份有限公司 使用活性维生素d化合物或其模拟物治疗、预防和缓解与化疗和放疗有关的肺部疾患
CN101171262A (zh) * 2005-05-04 2008-04-30 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
CN102659938A (zh) * 2005-05-04 2012-09-12 西兰制药公司 胰高血糖素样肽-2（glp-2）类似物
CN102711802A (zh) * 2009-10-23 2012-10-03 辉凌公司 肽glp-2激动剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PASCAL CRENN等: ""Postabsorptive Plasma Citrulline Concentration Is a Marker of Absorptive Enterocyte Mass and Intestinal Failure in Humans"", 《GASTROENTEROLOGY》 *
Y.M. PETERSEN等: ""Abstracts of the 20th Anniversary International MASCC/ISOO Symposium supportive care in cancer"", 《SUPPORT CARE CANCER》 *
李杭等: ""肠道缺血再灌注后GLP-2对黏膜增殖的影响"", 《浙江医学》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115054683A (zh) * 2022-05-19 2022-09-16 唐颢 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途

Also Published As

Publication number Publication date
AR103119A1 (es) 2017-04-19
PH12017500426A1 (en) 2017-07-31
AU2015313919A1 (en) 2017-03-16
MA40623A (fr) 2016-03-17
TW201613634A (en) 2016-04-16
BR112017004577A2 (pt) 2018-01-23
IL250928A0 (en) 2017-04-30
MX2017003166A (es) 2017-06-19
CL2017000563A1 (es) 2017-09-29
EP3191115A1 (en) 2017-07-19
EA201790552A1 (ru) 2017-08-31
KR20170052661A (ko) 2017-05-12
US20160067311A1 (en) 2016-03-10
CA2959110A1 (en) 2016-03-17
WO2016038455A1 (en) 2016-03-17
SG11201701690WA (en) 2017-04-27
JP2017532308A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
CN107073081A (zh) Elsiglutide治疗胃肠道黏膜炎包括化疗诱发的腹泻的应用
US20190290652A1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
KR20140011311A (ko) Ｐｉ３ｋ 억제제 및 ｍｅｋ 억제제를 포함하는 조성물 및 암을 치료하기 위한 이의 용도
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
US20120196828A1 (en) Sensitization of cancer cells to treatment
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
US11504365B2 (en) Use of tivozanib to treat subjects with refractory cancer
AU2021206140A1 (en) Combination therapy for treating cancer
US20230058171A1 (en) New oral pharmaceutical composition for cancer therapy
Di Lauro et al. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer
WO2016161615A1 (en) Method for treating cancer
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
US20230085602A1 (en) Pdac treatment regimen
Kim et al. Phase II clinical trial of Genexol (R)(paclitaxel) and carboplatin for patients with advanced non-small cell lung cancer
US20190117655A1 (en) Treatment of Biliary Duct Cancer
US20210113692A1 (en) Dosing regimen
WO2018063873A1 (en) Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
Park et al. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer
CN108883182A (zh) 用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗
KR20170118798A (ko) 다발성 골수종을 위한 파노비노스타트 투여
AU2012255772A1 (en) Medicaments and methods for treating cancer
Massard et al. 612 MOSCATO: a Molecular Screening Triage Trial for Patients Enrolled in Phase I Trials
WO2017201226A1 (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer
Koolen et al. Weekly oral docetaxel as solid dispersion (ModraDoc001 capsules) in combination with ritonavir is well tolerated and results in high exposure to docetaxel

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Lugano Switzerland / bazzero

Applicant after: Heersen health care Co Ltd

Applicant after: Sealand Pharmaceutical Co. Ltd.

Address before: Lugano Switzerland / bazzero

Applicant before: Helsinn Healthcare SA

Applicant before: Sealand Pharmaceutical Co. Ltd.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818

WD01 Invention patent application deemed withdrawn after publication